ATE322508T1 - Verwendung des antikörpers 271.14d9.f8 (dsm acc2331) um die bindung zwischen alphavbeta6- integrin und fibronectin in vitro zu hemmen - Google Patents

Verwendung des antikörpers 271.14d9.f8 (dsm acc2331) um die bindung zwischen alphavbeta6- integrin und fibronectin in vitro zu hemmen

Info

Publication number
ATE322508T1
ATE322508T1 AT99907361T AT99907361T ATE322508T1 AT E322508 T1 ATE322508 T1 AT E322508T1 AT 99907361 T AT99907361 T AT 99907361T AT 99907361 T AT99907361 T AT 99907361T AT E322508 T1 ATE322508 T1 AT E322508T1
Authority
AT
Austria
Prior art keywords
integrin
fibronectin
vitro
antibody
inhibit
Prior art date
Application number
AT99907361T
Other languages
English (en)
Inventor
Simon Goodman
Beate Diefenbach
Francesc Mitjans
Ana Carceller
Elisabet Rosell-Vives
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Application granted granted Critical
Publication of ATE322508T1 publication Critical patent/ATE322508T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT99907361T 1998-01-23 1999-01-11 Verwendung des antikörpers 271.14d9.f8 (dsm acc2331) um die bindung zwischen alphavbeta6- integrin und fibronectin in vitro zu hemmen ATE322508T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98101108 1998-01-23

Publications (1)

Publication Number Publication Date
ATE322508T1 true ATE322508T1 (de) 2006-04-15

Family

ID=8231295

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99907361T ATE322508T1 (de) 1998-01-23 1999-01-11 Verwendung des antikörpers 271.14d9.f8 (dsm acc2331) um die bindung zwischen alphavbeta6- integrin und fibronectin in vitro zu hemmen

Country Status (17)

Country Link
EP (1) EP1049718B1 (de)
JP (1) JP2002501086A (de)
KR (1) KR20010034327A (de)
CN (1) CN1168741C (de)
AR (1) AR014464A1 (de)
AT (1) ATE322508T1 (de)
AU (1) AU2716399A (de)
BR (1) BR9907218A (de)
CA (1) CA2319160A1 (de)
DE (1) DE69930723T2 (de)
HU (1) HUP0101151A3 (de)
ID (1) ID27810A (de)
NO (1) NO20003767D0 (de)
PL (1) PL341569A1 (de)
SK (1) SK10772000A3 (de)
WO (1) WO1999037683A1 (de)
ZA (1) ZA99453B (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3672800A (en) 1999-04-09 2000-11-14 Kyowa Hakko Kogyo Co. Ltd. Method for controlling the activity of immunologically functional molecule
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US20040136949A1 (en) 2001-04-24 2004-07-15 Matthias Grell Combination therapy using anti-angiogenic agents and tnf alpha
AU2002312566A1 (en) 2001-07-09 2003-01-29 Elan Pharmaceuticals, Inc. Methods of inhibiting amyloid toxicity
US7829087B2 (en) 2001-07-09 2010-11-09 Elan Pharmaceuticals, Inc. Methods of treating cognitive impairment
MY147019A (en) 2002-03-13 2012-10-15 Biogen Idec Inc Anti-alpha v beta 6 antibodies
CN102875681A (zh) * 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 抗-αvβ6抗体及其用途
EP2335733B1 (de) 2006-01-18 2014-08-06 Merck Patent GmbH Spezifische Krebsbehandlung mit Integrin-Liganden
CA2646611A1 (en) 2006-03-21 2008-05-22 Genentech, Inc. Combinatorial therapy
CN101563105B (zh) 2006-07-10 2013-01-23 拜奥根Idec马萨诸塞公司 用于抑制smad4-缺陷癌症的组合物和方法
WO2008112004A2 (en) 2006-08-03 2008-09-18 Astrazeneca Ab ANTIBODIES DIRECTED TO αVβ6 AND USES THEREOF
PT2101805E (pt) 2007-01-18 2013-01-31 Merck Patent Gmbh Terapia específica e medicamento usando ligandos integrina para tratar o cancro
AR066170A1 (es) 2007-09-26 2009-07-29 Genentech Inc Anti integrina alfa 5 beta 1
EP2730282A1 (de) 2007-11-08 2014-05-14 The General Hospital Corporation Verfahren und Zusammensetzung zur Behandlung von Proteinurie-Erkrankungen
MA33210B1 (fr) 2009-03-25 2012-04-02 Genentech Inc Nouveaux anticorps anti-a5b1 et leurs utilisations
EP2445534A2 (de) 2009-05-25 2012-05-02 Merck Patent GmbH Kontinuierliche verabreichung von cilengitid in der krebstherapie
BR112012020790B1 (pt) * 2010-02-18 2021-09-28 The Regents Of The University Of California Anticorpo isolado anti-integrina alfavbeta8 e composição farmacêutica
US10035859B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof
US10035860B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI0719859T1 (en) * 1994-12-20 2003-12-31 Merck Patent Gmbh Anti-alpha V-integrin monoclonal antibody

Also Published As

Publication number Publication date
PL341569A1 (en) 2001-04-23
HUP0101151A3 (en) 2004-06-28
AU2716399A (en) 1999-08-09
HUP0101151A2 (hu) 2001-08-28
KR20010034327A (ko) 2001-04-25
BR9907218A (pt) 2000-10-24
EP1049718A1 (de) 2000-11-08
DE69930723D1 (de) 2006-05-18
AR014464A1 (es) 2001-02-28
CN1288469A (zh) 2001-03-21
ZA99453B (en) 1999-07-21
CA2319160A1 (en) 1999-07-29
NO20003767L (no) 2000-07-21
DE69930723T2 (de) 2006-11-16
EP1049718B1 (de) 2006-04-05
JP2002501086A (ja) 2002-01-15
WO1999037683A1 (de) 1999-07-29
ID27810A (id) 2001-04-26
CN1168741C (zh) 2004-09-29
NO20003767D0 (no) 2000-07-21
SK10772000A3 (sk) 2001-01-18

Similar Documents

Publication Publication Date Title
ATE322508T1 (de) Verwendung des antikörpers 271.14d9.f8 (dsm acc2331) um die bindung zwischen alphavbeta6- integrin und fibronectin in vitro zu hemmen
IL142917A0 (en) Substituted 2-phenylbenzimidazoles, the production thereof and their use
HRP20120132A8 (hr) Azabicikloalkani u svojstvu modulatora ccr5
PL347684A1 (en) 2-phenylbenzimidazoles and 2-phenylindoles, and production and use thereof
DE59709806D1 (de) Cycloolefincopolymere, ihre verwendung und daraus hergestellte formkörper
ATE239693T1 (de) 3,3-diarylpropylamine , ihre verwendung und herstellung
DE69709315D1 (de) Weichmacherlotionzusammensetzung, ihre verwendung in der papierherstellung und papierprodukt
HUP9900163A3 (en) Process for the preparation of sterol-and stanol-esters, and use thereof
ATE272634T1 (de) Benzothiophenderivate, verhahren zu ihrer herstellung und ihre verwendung
HUP0101624A3 (en) New substituted amides, their production and their use
AU2608602A (en) Silensed anti-cd28 antibodies and use thereof
ZA200202816B (en) Modified plant viruses and methods of use thereof.
ID21155A (id) Katalis amoksidasi untuk digunakan dalam produksi akrilonitril atau metakrilonitril dari propana atau isobutana melalui amoksidasi
GB9927332D0 (en) Novel antibody and uses thereof
ATE439439T1 (de) Disulfid-vernetzte glycoprotein-hormone, ihre herstellung und verwendung
HUP0101475A3 (en) 4,5,6 and 7-indole and indoline derivatives, their preparation and use
IT1294441B1 (it) Impianto per il colaggio in pressione di articoli sanitari
DE69527779D1 (de) Etherverbindungen, ihre verwendung und zwischenprodukte zu ihrer herstellung
EP1207150A4 (de) Langkettige n-epsilon acyllysin-kristalle, verfahren zu ihrer herstellung und kosmetika, die diese enthalten
DE69811651D1 (de) Enthaarungszusammensetzungen, die bereitung und die verwendung derselben
ITRM950316A0 (it) Materiale in lega per tissofusione, procedimento per la preparazione del materiale in lega semi-fuso per tissofusione e procedimento di tissofusione.
IS5731A (is) 4, 5, 6 og 7-indól og indólín afleiður, framleiðsla þeirra og notkun
DE19980266D2 (de) CVD-Reaktor und dessen Verwendung
DE50107204D1 (de) 8beta-substituierte-11beta-pentyl-und 11beta-hexyl-estra-1,3,5(10)-trienderivate
DE69933035D1 (de) Antikariogenisches milchprodukt und dessen verwendung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties